DACLIZUMAB
UNII CUJ2MVI71Y

Substance Identification & Data

This profile provides standardized clinical and technical data for Daclizumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) CUJ2MVI71Y.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 152923-56-3 and the RxNorm Concept ID (RxCUI) 190353. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

CUJ2MVI71Y

CAS Registry Number

152923-56-3

RxNorm Concept ID

190353

Detailed Substance Profile

Preferred Name

DACLIZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C1569

National Cancer Institute reference terminology for clinical and research data.

INN ID

7164

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

FF-43 2

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Daclizumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.